Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 2
2008 2
2010 2
2011 1
2012 3
2013 1
2014 1
2015 1
2016 2
2017 7
2018 8
2019 11
2020 15
2021 20
2022 15
2023 17
2024 14

Text availability

Article attribute

Article type

Publication date

Search Results

112 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean delay rodriguez abreu (6 results)?
Pembrolizumab Plus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After 5 Years of Follow-Up.
Gadgeel SM, Rodríguez-Abreu D, Halmos B, Garassino MC, Kurata T, Cheng Y, Jensen E, Shamoun M, Rajagopalan K, Paz-Ares L. Gadgeel SM, et al. Among authors: rodriguez abreu d. J Thorac Oncol. 2024 Apr 18:S1556-0864(24)00169-2. doi: 10.1016/j.jtho.2024.04.011. Online ahead of print. J Thorac Oncol. 2024. PMID: 38642841
The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy.
Gómez Rueda A, Taus Á, Álvarez Álvarez R, Bernabé-Caro R, Chara L, López-Brea M, Vilà L, Sala González MÁ, Del Barrio Díaz Aldagalán A, Esteban Herrera B, López Castro R, Álvarez Cabellos R, Doménech M, Falagan S, Moreno Vega A, Aguado C, Barba A, Delgado Ureña MT, Isla D, Bellido Hernández L, Fírvida Pérez JL, Juan-Vidal Ó, Massutí B, Mielgo-Rubio X, Ortega AL, Catot S, Dómine M, Escoín-Pérez C, García Navalón F, Gil-Bazo I, Muñoz S, Rodríguez-Abreu D, Villatoro Roldán RM, Alonso-Jáudenes Curbera G, León-Mateos L, Padilla A, Paredes Lario A, Sánchez-Torres JM, Garrido P; Spanish Lung Cancer Group. Gómez Rueda A, et al. Among authors: rodriguez abreu d. Clin Transl Oncol. 2024 Mar 21. doi: 10.1007/s12094-024-03404-9. Online ahead of print. Clin Transl Oncol. 2024. PMID: 38512450
Publisher Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells.
Guan X, Hu R, Choi Y, Srivats S, Nabet BY, Silva J, McGinnis L, Hendricks R, Nutsch K, Banta KL, Duong E, Dunkle A, Chang PS, Han CJ, Mittman S, Molden N, Daggumati P, Connolly W, Johnson M, Abreu DR, Cho BC, Italiano A, Gil-Bazo I, Felip E, Mellman I, Mariathasan S, Shames DS, Meng R, Chiang EY, Johnston RJ, Patil NS. Guan X, et al. Among authors: abreu dr. Nature. 2024 Mar;627(8005):E11. doi: 10.1038/s41586-024-07280-9. Nature. 2024. PMID: 38480897 No abstract available.
CD8+ NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent/refractory diffuse large B cell lymphoma.
Hontecillas-Prieto L, García-Domínguez DJ, Palazón-Carrión N, Martín García-Sancho A, Nogales-Fernández E, Jiménez-Cortegana C, Sánchez-León ML, Silva-Romeiro S, Flores-Campos R, Carnicero-González F, Ríos-Herranz E, de la Cruz-Vicente F, Rodríguez-García G, Fernández-Álvarez R, Martínez-Banaclocha N, Gumà-Padrò J, Gómez-Codina J, Salar-Silvestre A, Rodríguez-Abreu D, Gálvez-Carvajal L, Labrador J, Guirado-Risueño M, Provencio-Pulla M, Sánchez-Beato M, Marylene L, Álvaro-Naranjo T, Casanova-Espinosa M, Rueda-Domínguez A, Sánchez-Margalet V, de la Cruz-Merino L. Hontecillas-Prieto L, et al. Among authors: rodriguez abreu d. Front Immunol. 2024 Feb 26;15:1293931. doi: 10.3389/fimmu.2024.1293931. eCollection 2024. Front Immunol. 2024. PMID: 38469299 Free PMC article. Clinical Trial.
Describing differences among populations of thoracic tumors patients under and over 80 years: Data analysis from the SLCG thoracic tumor registry.
Provencio M, Cobo M, Rodriguez-Abreu D, Carcereny E, Cantero A, Calvo V, López Castro R, Bernabé R, Bosch-Barrera J, Massutí B, García Campelo R, Sánchez-Hernández A, Laura Ortega A, Guirado M, Del Barco E, Camps C, Casal-Rubio J, Dómine M, Angeles Sala M, Padilla A, Luís González Larriba J, de Asís Aparisi F; Spanish Lung Cancer Group SLCG/GECP. Provencio M, et al. Among authors: rodriguez abreu d. Lung Cancer. 2024 Apr;190:107513. doi: 10.1016/j.lungcan.2024.107513. Epub 2024 Feb 29. Lung Cancer. 2024. PMID: 38432027
Blood tumor mutational burden and response to pembrolizumab plus chemotherapy in non-small cell lung cancer: KEYNOTE-782.
Bar J, Esteban E, Rodríguez-Abreu D, Aix SP, Szalai Z, Felip E, Gottfried M, Provencio M, Robinson A, Fülöp A, Rao SB, Camidge DR, Speranza G, Townson SM, Kobie J, Ayers M, Dettman EJ, Hunkapiller N, McDaniel R, Jung B, Burkhardt D, Mauntz R, Csőszi T. Bar J, et al. Among authors: rodriguez abreu d. Lung Cancer. 2024 Apr;190:107506. doi: 10.1016/j.lungcan.2024.107506. Epub 2024 Feb 17. Lung Cancer. 2024. PMID: 38422883 Free article.
Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells.
Guan X, Hu R, Choi Y, Srivats S, Nabet BY, Silva J, McGinnis L, Hendricks R, Nutsch K, Banta KL, Duong E, Dunkle A, Chang PS, Han CJ, Mittman S, Molden N, Daggumati P, Connolly W, Johnson M, Abreu DR, Cho BC, Italiano A, Gil-Bazo I, Felip E, Mellman I, Mariathasan S, Shames DS, Meng R, Chiang EY, Johnston RJ, Patil NS. Guan X, et al. Among authors: abreu dr. Nature. 2024 Mar;627(8004):646-655. doi: 10.1038/s41586-024-07121-9. Epub 2024 Feb 28. Nature. 2024. PMID: 38418879
STAR-121: A Phase III Randomized Study of Domvanalimab and Zimberelimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Untreated Metastatic Non-Small Cell Lung Cancer With No Actionable Gene Alterations.
Rodriguez-Abreu D, Bosch-Barrera J, Gray JE, Ahn MJ, Johnson M, Yu X, Mohammad S, Chen X, Todd T, Kim J, Reck M. Rodriguez-Abreu D, et al. Clin Lung Cancer. 2024 Jan 6:S1525-7304(23)00267-X. doi: 10.1016/j.cllc.2023.12.010. Online ahead of print. Clin Lung Cancer. 2024. PMID: 38310035
Identification of non-actionable mutations with prognostic and predictive value in patients with advanced or metastatic non-small cell lung cancer.
Provencio-Pulla M, Pérez-Parente D, Olson S, Hasan H, Balea BC, Rodríguez-Abreu D, Piqueras ML, Pal N, Wilkinson S, Vilas E, Ruiz-Gracia P, Cobo-Dols M. Provencio-Pulla M, et al. Among authors: rodriguez abreu d. Clin Transl Oncol. 2024 Jan 6. doi: 10.1007/s12094-023-03362-8. Online ahead of print. Clin Transl Oncol. 2024. PMID: 38183584
112 results